Wells Fargo’s Alexion Pharmaceuticals ALXN Stock Holding History

Wells Fargo’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-45,800	Closed	-$635K	–	7130
2020 Q1	$635K	Hold	45,800	–	–	﹤0.01%	3862
2019 Q4	$314K	Buy	45,800 +45,500	+15,167%	+$4.87M	﹤0.01%	4704
2019 Q3	$5K	Hold	300	–	–	﹤0.01%	6086
2019 Q2	$1K	Hold	300	–	–	﹤0.01%	6320
2019 Q1	$2K	Buy	+300	New	+$37.3K	﹤0.01%	5891
2018 Q1	–	Sell	-29,800	Closed	-$480K	–	6667
2017 Q4	$480K	Buy	+29,800	New	+$3.63M	﹤0.01%	4436
2017 Q2	–	Sell	-50,000	Closed	-$412K	–	6554
2017 Q1	$412K	Buy	+50,000	New	+$6.45M	﹤0.01%	4371

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wells Fargo's ALXN Position: Q3 2021 in Review

Wells Fargo sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 904,290 shares — an estimated $166M sold.

Wells Fargo first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.14B in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Wells Fargo reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Wells Fargo sold 904,290 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
Wells Fargo first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Wells Fargo's Alexion Pharmaceuticals position peaked at $1.14B in Q4 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.